News | April 11, 2021
NATCO receives approval for Ibrutinib tablets from ANDA
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
ranules now has a total of 38 ANDA approvals from US FDA.
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
Subscribe To Our Newsletter & Stay Updated
